John Higgins just Sold 22,500 shares of Ligand Pharmaceuticals (LGND), be careful if you are long!; Milestone Scientific (MS) Sentiment Is 0.94

Ligand Pharmaceuticals Inc’s Chief Executive Officer, John Higgins, sold 22,500 shares of stock in the stock exchange listed company. The average per share price was $165.0, for aggregate sale worth of $3,712,500 US Dollars. In the last 30 days, he also sold 28,099 shares worth $4,318,902 USD. John Higgins now indirectly has ownership of 0 shares. He also directly has ownership of 111700 shares. In total he holds a stake of 0.53%. The dated January 26, 2018 transaction’s report which was filed with the Security and Exchange Commission is accessible for free here.

Morgan Stanley, a financial holding company, provides various financial services and products to firms, governments, financial institutions, and individuals in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company has market cap of $102.99 billion. The companyÂ’s Institutional Securities segment offers capital raising and financial advisory services, including services related to the underwriting of debt, equity, and other securities, as well as advice on mergers and acquisitions, restructurings, real estate, and project finance. It has a 18.64 P/E ratio. This segment also provides sales and trading services, such as sales, financing, and market-making services in equity securities and fixed income products, including foreign exchange and commodities, as well as prime brokerage services; corporate loans, commercial and residential mortgage lending, and asset-backed lending; financing for equities and commodities customers; loans to municipalities; and investments and research services.

Mitsubishi Ufj Financial Group Inc holds 100% of its portfolio in Morgan Stanley for 432.02 million shares. Valueact Holdings L.P. owns 17.88 million shares or 8.63% of their US portfolio. Moreover, Wellcome Trust Ltd (The) As Trustee Of The Wellcome Trust has 6.5% invested in the company for 8.45 million shares. The Oklahoma-based Gibraltar Capital Management Inc. has invested 6.47% in the stock. Kiltearn Partners Llp, a United Kingdom-based fund reported 4.34 million shares.

The stock increased 1.39% or $0.79 during the last trading session, reaching $57.6. About 8.38 million shares traded or 3.80% up from the average. Morgan Stanley (MS) has risen 57.08% since January 27, 2017 and is uptrending. It has outperformed by 40.38% the S&P500.

Ratings analysis reveals 50% of Morgan Stanley’s analysts are positive. Out of 4 Wall Street analysts rating Morgan Stanley, 2 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. MS was included in 4 notes of analysts from October 6, 2016. Guggenheim upgraded Morgan Stanley (NYSE:MS) on Thursday, October 20 to “Buy” rating. The firm has “Buy” rating by Societe Generale given on Wednesday, January 11. Barclays Capital maintained Morgan Stanley (NYSE:MS) on Thursday, October 20 with “Equal Weight” rating. Sandler O’Neill downgraded the stock to “Hold” rating in Thursday, October 6 report.

Analysts await Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to report earnings on February, 22. They expect $0.92 earnings per share, up 713.33% or $1.07 from last year’s $-0.15 per share. LGND’s profit will be $19.42M for 45.07 P/E if the $0.92 EPS becomes a reality. After $0.55 actual earnings per share reported by Ligand Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts 67.27% EPS growth.

Since August 8, 2017, it had 0 insider purchases, and 8 insider sales for $9.54 million activity. 5,000 shares were sold by HIGGINS JOHN L, worth $650,000. Another trade for 2,000 shares valued at $255,980 was sold by Aryeh Jason. $2.36 million worth of stock was sold by Berkman Charles S on Wednesday, August 9. FOEHR MATTHEW W had sold 6,100 shares worth $777,824 on Wednesday, August 9. The insider Sabba Stephen L sold 925 shares worth $126,956. KOZARICH JOHN W also sold $362,500 worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) shares.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company has market cap of $3.50 billion. The Company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. It has a 212.34 P/E ratio. The companyÂ’s partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others.

Among 6 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Ligand Pharmaceuticals has $170.0 highest and $103 lowest target. $149.67’s average target is -9.75% below currents $165.84 stock price. Ligand Pharmaceuticals had 24 analyst reports since September 3, 2015 according to SRatingsIntel. Stephens initiated the stock with “Overweight” rating in Wednesday, April 13 report. The company was maintained on Thursday, November 9 by H.C. Wainwright. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has “Sell” rating given on Friday, August 5 by Deutsche Bank. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) earned “Buy” rating by Roth Capital on Wednesday, October 11. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) earned “Buy” rating by Roth Capital on Wednesday, September 30. The firm has “Buy” rating given on Friday, December 18 by TH Capital. The company was downgraded on Monday, November 20 by Deutsche Bank. The company was maintained on Friday, March 11 by Roth Capital. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) earned “Hold” rating by Deutsche Bank on Tuesday, August 8. The rating was maintained by TH Capital on Thursday, November 19 with “Buy”.

Investors sentiment increased to 1.69 in 2017 Q3. Its up 0.45, from 1.24 in 2017Q2. It improved, as 19 investors sold Ligand Pharmaceuticals Incorporated shares while 68 reduced holdings. 50 funds opened positions while 97 raised stakes. 22.76 million shares or 0.86% more from 22.57 million shares in 2017Q2 were reported. Elk Creek Prtnrs Ltd Liability Company owns 130,905 shares for 1.12% of their portfolio. Da Davidson & Com stated it has 2,730 shares. Atria Invests Ltd Company invested in 0.02% or 3,292 shares. American Century has 0% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 14,488 shares. Hsbc Public Ltd Com holds 0.01% or 34,048 shares. Eqis Capital holds 0.06% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) or 8,215 shares. Campbell Newman Asset invested 0.07% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). First Personal Svcs has invested 0% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Ameriprise Fincl holds 0.02% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 383,919 shares. Raymond James And Associates stated it has 8,752 shares or 0% of all its holdings. Texas Permanent School Fund, a Texas-based fund reported 15,273 shares. Piedmont Advisors owns 4,556 shares or 0.01% of their US portfolio. Cortina Asset Mngmt Limited Co reported 45,134 shares stake. Quantitative Investment Mgmt Lc has invested 0.04% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Colorado-based Public Employees Retirement Association Of Colorado has invested 0% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND).

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: